BRPI0709847B8 - composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio - Google Patents

composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio

Info

Publication number
BRPI0709847B8
BRPI0709847B8 BRPI0709847A BRPI0709847A BRPI0709847B8 BR PI0709847 B8 BRPI0709847 B8 BR PI0709847B8 BR PI0709847 A BRPI0709847 A BR PI0709847A BR PI0709847 A BRPI0709847 A BR PI0709847A BR PI0709847 B8 BRPI0709847 B8 BR PI0709847B8
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
calcium carbonate
fast
composition containing
solid pharmaceutical
Prior art date
Application number
BRPI0709847A
Other languages
English (en)
Inventor
H Alur Hemant
Original Assignee
GlaxoSmithKline Consumer Healthcare UK IP Ltd
Glaxosmithkline Consumer Healthcare Invest Ireland No 2
Glaxosmithkline Consumer Healthcare Investments Ireland No 2 Ltd
Glaxosmithkline Consumer Healthcare Invest Ireland No 2 Unlimited Company
Glaxosmithkline Dungarvan Ltd
Glaxosmithkline Llc
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Consumer Healthcare UK IP Ltd, Glaxosmithkline Consumer Healthcare Invest Ireland No 2, Glaxosmithkline Consumer Healthcare Investments Ireland No 2 Ltd, Glaxosmithkline Consumer Healthcare Invest Ireland No 2 Unlimited Company, Glaxosmithkline Dungarvan Ltd, Glaxosmithkline Llc, Smithkline Beecham Corp filed Critical GlaxoSmithKline Consumer Healthcare UK IP Ltd
Publication of BRPI0709847A2 publication Critical patent/BRPI0709847A2/pt
Publication of BRPI0709847B1 publication Critical patent/BRPI0709847B1/pt
Publication of BRPI0709847B8 publication Critical patent/BRPI0709847B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin

Abstract

composição farmacêutica, tablete deglutível, uso de uma composição, processo para preparar uma composição farmacêutica uma composição farmacêutica tal como uma formulação em tablete ou cápsula para deglutição é descrita, compreendendo paracetamol, carbonato de cálcio, pelo menos um agente de aglutinação e pelo menos um agente desintegrante na forma de um granulado, opcionalmente combinados com um ou mais componentes extragranulares farmaceuticamente aceitáveis.
BRPI0709847A 2006-04-07 2007-04-03 composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio BRPI0709847B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0607085.8A GB0607085D0 (en) 2006-04-07 2006-04-07 Novel compositions
GB0607085.8 2006-04-07
PCT/US2007/065829 WO2007118063A1 (en) 2006-04-07 2007-04-03 Fast release paracetamol tablets

Publications (3)

Publication Number Publication Date
BRPI0709847A2 BRPI0709847A2 (pt) 2011-07-26
BRPI0709847B1 BRPI0709847B1 (pt) 2020-09-15
BRPI0709847B8 true BRPI0709847B8 (pt) 2021-05-25

Family

ID=36539581

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0709847A BRPI0709847B8 (pt) 2006-04-07 2007-04-03 composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio

Country Status (15)

Country Link
US (1) US8461210B2 (pt)
EP (1) EP2010159B1 (pt)
CN (1) CN101466359B (pt)
AU (1) AU2007234864B2 (pt)
BR (1) BRPI0709847B8 (pt)
CA (1) CA2648725A1 (pt)
CR (1) CR10349A (pt)
DK (1) DK2010159T3 (pt)
EA (1) EA017157B1 (pt)
GB (1) GB0607085D0 (pt)
MX (1) MX2008012731A (pt)
MY (1) MY147641A (pt)
NO (1) NO20084065L (pt)
NZ (1) NZ571624A (pt)
WO (1) WO2007118063A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0813929D0 (en) * 2008-07-30 2008-09-03 Glaxo Group Ltd Novel method
US20130108699A1 (en) * 2010-04-26 2013-05-02 Jose Antonio Matji Tuduri Highly dispersible granulate for the preparation of formulations of high dosage active substances and procedure for obtaining high dosage active substances thereof
US9446000B2 (en) * 2011-09-08 2016-09-20 Masdar Institute Of Science And Technology Cellulosic gel material as a pharmaceutical excipient
US20140128415A1 (en) * 2012-05-30 2014-05-08 Paul Daniel Yered Excipient drug composition
CN103110637B (zh) * 2013-02-19 2014-07-30 青岛正大海尔制药有限公司 酚咖胶囊及其制备方法
BE1021194B1 (nl) * 2014-07-07 2015-07-14 Nordic Specialty Pharma Bvba Paracetamol tabletten
CN105310990B (zh) * 2014-12-04 2018-01-19 蚌埠丰原涂山制药有限公司 一种防止粘冲和裂片的对乙酰氨酚片及其制备方法
BE1023116B1 (nl) * 2015-07-24 2016-11-23 Nordic Specialty Pharma Bvba Paracetamol omvattend preparaat met vertraagde en aanhoudende afgifte
CN105055329A (zh) * 2015-08-05 2015-11-18 安丘市鲁安药业有限责任公司 复合扑热息痛速溶颗粒及其制备方法
CN106265573A (zh) * 2016-09-23 2017-01-04 广东岭南职业技术学院 一种扑热息痛片生产中hpmc浆的制备工艺
CN108451916B (zh) * 2018-06-19 2020-08-14 重庆国泰康宁制药有限责任公司 一种对乙酰氨基酚药物组合物制剂及其制备方法
CN108853038A (zh) * 2018-08-06 2018-11-23 成都通德药业有限公司 一种对乙酰氨基酚片及其制备工艺
CN111374953A (zh) * 2018-12-31 2020-07-07 上海鼎雅药物化学科技有限公司 对乙酰氨基酚片及其制备工艺
EP3679926A1 (en) * 2019-01-14 2020-07-15 APTYS Pharmaceuticals SAS A method of manufacturing a pharmaceutical composition comprising nefopam and acetaminophen, and the pharmaceutical composition obtained thereby
CN110101672A (zh) * 2019-05-07 2019-08-09 安徽金太阳生化药业有限公司 一种对乙酰氨基酚片及其制备方法
CN111012750A (zh) * 2019-12-27 2020-04-17 北京济美堂医药研究有限公司 一种对乙酰氨基酚片及其制备方法
GB202007670D0 (en) 2020-05-22 2020-07-08 Glaxosmithkline Consumer Healthcare Holdings Us Llc Pharmaceutical composition
CN114129524A (zh) * 2021-09-30 2022-03-04 山东齐都药业有限公司 对乙酰氨基酚片剂及其制备方法
CN114432256A (zh) * 2021-12-31 2022-05-06 陕西必康制药集团控股有限公司 对乙酰氨基酚包衣片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1182049A (en) 1981-07-13 1985-02-05 Francis J. Sterbenz Apap antacid composition
CA2009326C (en) * 1989-05-09 1998-01-27 Lawrence J. Daher Aqueous granulation solution and a method of tablet granulation
CA2021548A1 (en) * 1989-09-01 1991-03-02 Ronald Nash Duvall Effervescent cold or sinus allergy medicine composition having reduced sodium content
GB9704524D0 (en) 1997-03-05 1997-04-23 Smithkline Beecham Plc Composition
GB0114069D0 (en) 2001-06-08 2001-08-01 Smithkline Beecham Plc Composition
ES2624585T3 (es) 2004-05-28 2017-07-17 Imaginot Pty Ltd. Sistema de suministro de compuesto terapéutico oral
US20050276847A1 (en) * 2004-05-28 2005-12-15 Roberts Michael S Oral delivery system
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
CN101048155A (zh) 2004-10-28 2007-10-03 诺瓦提斯公司 含有对乙酰氨基酚、咖啡因和任选的阿司匹林以及用于增强吸收的碱性剂的组合物
EP3449928A1 (en) 2005-11-28 2019-03-06 Imaginot Pty Ltd. Oral therapeutic compound delivery system

Also Published As

Publication number Publication date
AU2007234864A1 (en) 2007-10-18
EP2010159B1 (en) 2012-08-22
BRPI0709847B1 (pt) 2020-09-15
BRPI0709847A2 (pt) 2011-07-26
CR10349A (es) 2008-11-26
NZ571624A (en) 2011-11-25
CN101466359B (zh) 2013-09-25
WO2007118063A1 (en) 2007-10-18
CA2648725A1 (en) 2007-10-18
DK2010159T3 (da) 2012-10-22
EP2010159A1 (en) 2009-01-07
US8461210B2 (en) 2013-06-11
MY147641A (en) 2012-12-31
AU2007234864B2 (en) 2012-11-22
US20090170955A1 (en) 2009-07-02
CN101466359A (zh) 2009-06-24
EA200801926A1 (ru) 2009-04-28
EA017157B1 (ru) 2012-10-30
MX2008012731A (es) 2008-10-14
NO20084065L (no) 2008-10-30
GB0607085D0 (en) 2006-05-17

Similar Documents

Publication Publication Date Title
BRPI0709847B8 (pt) composição farmacêutica sólida de liberação rápida contendo paracetamol e carbonato de cálcio
IL195294A (en) A process for the manufacture of high purity spinamide or relapinamide, their use in the preparation of medicaments and medicinal preparations containing them
CL2018001420A1 (es) Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma. (divisional solicitud 201701853)
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
MX2009004203A (es) Combinaciones de paracetamol/ibuprofeno y metodo para su uso.
BRPI0707044B8 (pt) comprimido matricial insolúvel em água e processo de fabricação de comprimidos matriciais
ECSP088239A (es) Composición de liberación de fármaco sostenida
PE20061091A1 (es) FORMA CRISTALINA BETA-d DEL CLORHIDRATO DE IVABRANDINA, SU PROCEDIMIENTO DE PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LA CONTIENEN
MX2010007609A (es) Formulacion de capsula.
BR112014018378A8 (pt) Processo contínuo para a preparação de um comprimido compreendendo ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol5-il) ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico
BRPI0606883A2 (pt) composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única
UY29086A1 (es) Nuevas composiciones farmacéuticas para el tratamiento de trastornos hiperproliferativos.
BRPI0906181A2 (pt) "método para tratamento de uma disfunção hiperproliferativa, composição farmacêutica, uso de uma combinação terapêutica na fabricação de um medicamento para o tratamento de câncer, artigo de fabricação para tratamento de uma disfunção hiperproliferativa, método para determinação de compostos a serem usados em combinação para o tratamento de câncer e método para determinação de uma combinação terapêutica a ser usada para o tratamento de câncer"
TN2009000093A1 (en) Pharmaceutical compositions comprising nilotinib or its salt
BR112012023324B8 (pt) processo de preparação de uma forma de dosagem multifásica liofilizada de dissolução rápida
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
AR034900A1 (es) Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica
MX2010007083A (es) Combinacion anti-retroviral.
CO6640264A2 (es) Combinación de gránulos cargados activos con activos adicionales
TR200604349A2 (tr) Aripiprazol içeren farmasötik bileşimler
CL2007001838A1 (es) Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih.
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
AR061093A1 (es) Composiciones de calcio
BG109430A (en) FLUKOONAZOLE CAPSULES WITH IMPROVED EXEMPTION

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: GLAXOSMITHKLINE LLC (US)

B25G Requested change of headquarter approved

Owner name: GLAXOSMITHKLINE DUNGARVAN LIMITED (IE)

B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE DUNGARVAN LIMITED (IE)

B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENTS (I

B25D Requested change of name of applicant approved

Owner name: GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENTS (I

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Notification to applicant to reply to the report for non-patentability or inadequacy of the application [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 15/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B25D Requested change of name of applicant approved

Owner name: GLAXOSMITHKLINE CONSUMER HEALTHCARE INVESTMENTS (IRELAND) (NO. 2) UNLIMITED COMPANY (IE)

B16C Correction of notification of the grant

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/04/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: GLAXOSMITHKLINE CONSUMER HEALTHCARE (UK) IP LIMITED (GB)